Nutex Health, Inc.

Is Nutex Health, Inc. overvalued or undervalued?

As of October 17, 2025, Nutex Health, Inc. is considered very attractive due to its low P/E ratio of 5, strong EV to EBITDA ratio of 2.82, exceptional profitability metrics (ROCE of 128.63% and ROE of 76.34%), and a remarkable stock return of 326.80% over the past year, significantly outperforming the S&P 500.

As of 17 October 2025, the valuation grade for Nutex Health, Inc. has moved from attractive to very attractive. Based on the current metrics, the company appears to be undervalued. The P/E ratio stands at 5, significantly lower than the industry average, while the EV to EBITDA ratio is 2.82, indicating strong earnings relative to enterprise value. Additionally, the company boasts an impressive ROCE of 128.63% and ROE of 76.34%, reflecting exceptional profitability.<BR><BR>In comparison to its peers, Nutex Health, Inc. has a more favorable EV to EBITDA ratio than Fulgent Genetics, Inc., which is at -8.0743, and Talkspace, Inc., which is at -344.3683. This suggests that Nutex is performing better in terms of operational efficiency and value creation. Over the past year, Nutex Health has delivered a remarkable stock return of 326.80%, significantly outperforming the S&P 500's return of 14.08%, reinforcing the notion of its undervaluation.

Is Nutex Health, Inc. technically bullish or bearish?

As of June 9, 2025, Nutex Health, Inc. shows a mildly bullish trend with mixed technical signals, having outperformed the S&P 500 significantly year-to-date with a return of 193.34% compared to 12.22%.

As of 9 June 2025, the technical trend for Nutex Health, Inc. has changed from bullish to mildly bullish. The weekly MACD is mildly bearish, while the monthly MACD is mildly bullish, indicating mixed signals. The daily moving averages are mildly bullish, supporting the overall mildly bullish stance. However, the weekly Bollinger Bands and KST are bearish, and the Dow Theory shows a mildly bullish weekly but mildly bearish monthly outlook. <BR><BR>In terms of performance, Nutex Health has significantly outperformed the S&P 500 year-to-date with a return of 193.34% compared to the S&P 500's 12.22%, and over the past year, it has returned 273.93% versus the S&P 500's 17.14%.

How big is Nutex Health, Inc.?

As of Jun 18, Nutex Health, Inc. has a market capitalization of 641.62 million and net sales of 624.28 million with a net profit of 140.03 million over the latest four quarters. Shareholder's funds are 146.34 million, and total assets amount to 669.90 million.

As of Jun 18, Nutex Health, Inc. has a market capitalization of 641.62 million, which classifies it as a Micro Cap company.<BR><BR>As of Jun 18, the sum of net sales for the latest four quarters is 624.28 million, while the sum of net profit for the same period is 140.03 million.<BR><BR>As of Dec 24, the reporting period shows shareholder's funds of 146.34 million and total assets amounting to 669.90 million.

What does Nutex Health, Inc. do?

Nutex Health, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, with recent net sales of $212 million and a net profit of $44 million. Key metrics include a P/E ratio of 5.00 and a return on equity of 76.34%.

Overview:<BR>Nutex Health, Inc. operates in the Pharmaceuticals & Biotechnology industry and is classified as a micro-cap company.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 212 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 44 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 641.62 Million (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 5.00 <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.18 <BR>Return on Equity: 76.34% <BR>Price to Book: 3.26 <BR><BR>Contact Details:<BR>Details: No Company Details Available <BR>Registrar Address: Not available.

Should I buy, sell or hold Nutex Health, Inc.?